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Abstract 
Botulinum toxin (BTX) is a neurotoxin derived from the Clostridium botulinum bacterium that inhibits the release of 
acetylcholine at the neuromuscular junction level whose effects has been used for many years to treat a variety of 
muscular/neuromuscular conditions and more recently also for cosmetic use. 
BTX has experimented in some dermatological conditions, which include Rosacea and facial flushing treatment 
with good results. The complex mechanism underlying those results is not completely understood but was 
proposed a release inhibition of acetylcholine from peripheral autonomic nerves of the cutaneous vasodilatory 
system combined with the blockade substance P and calcitonin gene-related peptide (CGRP) thus modulating 
blood vessel dilatation. 
We analysed the published data on BTX off label applications rosacea and flushing retrieved from PubMed. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Botulinum toxin (BTX) is a neurotoxin derived 
from the Clostridium botulinum bacterium that exerts 
its effect at the neuromuscular junction cleaving a 
docking protein (synaptosomal-associated protein of 
25 kDa [SNAP-25]) on the internal surface of neuronal 
membranes, thereby inhibiting vesicle fusion and 
release of acetylcholine thus causing a temporary 
chemical denervation [1] . BTX effects in the targeted 
muscles diminish over time as SNAP-25 regenerates, 
and contractility is restored in a variable time of a few 
months. 
Those effects, used for many years to treat a 
variety of muscular/neuromuscular conditions in 2002 
was also approved for cosmetic use to treat complex 
glabellar muscles that form frown lines first and to 
treat lateral orbicularis oculi muscles that form crow's 
feet later [2]. 
 
More recently, BTX has experimented in 
some dermatological conditions which include 
Rosacea and facial flushing treatment with good 
results [3], [4], [5], [6]. The good results of those off 
label uses could be explained with the widely known 
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interaction between skin and nervous system and is 
supposed that BTX may inhibit the release of 
substance P, calcitonin gene-related peptide (CGRP) 
and glutamate modulating cutaneous inflammation 
and wound healing. 
 
 
Material and Methods  
 
We analysed the published data on BTX off 
label applications on rosacea and facial flushing 
retrieved from PubMed. We found 39 articles, from 
2005 to April 2017 using the terms “botulin rosacea” 
and “botulin flushing” plus all correlated MeSH terms. 
Of these articles, only 30 were included in this review. 
Exclusion criteria were: duplicated studies, papers 
focusing on topics not related to dermatology or 
plastic surgery (like many papers on flushing related 
to Frey syndrome) and articles written in languages 
other than English.  
 
 
Results 
 
BTX has been used to treat rosacea or facial 
flushing in a small number of studies [7], [8], [9], [10], 
[11], [12], [13], [14] and only one was made as 
randomized controlled trials with the efficacy of BTX 
compared to placebo (saline solution). All works, 
randomised and not, while all using intradermal 
injections, differ for the amount of BTX used ranging 
from 1 to 6 IU every cm2 of affected skin and for the 
frequency of treatment ranging from a single 
treatment to three treatments done with different 
intervals, but all gave positive results. 
Single-arm pilot studies involving patients with 
facial flushing were done and showed an 
improvement within a variable time ranging from 2 
weeks to 3 months after a single treatment of a 
variable dose of BTX (from 1 to 2 IU/cm2) [9], [10], 
[12], [13], [14], while the only randomized controlled 
trial followed for 6 months 60 patients with 
menopausal hot flushes treated with a single injection 
of 6,2 IU of BTX per cm2 versus 0,9% saline solution 
and showed a significant reduction in the mean 
number of menopausal hot flashes after 2 months. 
The effect of BTX was also investigated in 15 patients 
with rosacea. Treated with a single dose of 15–45 IU 
of BTX to face which resulted in a statistically 
significant of erythema grade, as compared to 
baseline, at 1, 2, and 3 months after treatment (P       
< 0.05, P < 0.001, and P < 0.05, respectively) [9]. 
 
 
Discussion 
 
Facial flushing consists of an episode of 
redness often associated with a burning sensation. It 
can be primary or idiopathic and secondary to rosacea 
or hormonal stimuli like menopause; rosacea is a 
common inflammatory dermatosis also characterised 
by persistent erythema, telangiectasia, papules and 
pustules [15].A possible mechanism by which BTX 
improves flushing and rosacea is the blockade of 
acetylcholine release from peripheral autonomic 
nerves of the cutaneous vasodilatory system [16], 
[17]. Is also known that BTX inhibits the release of 
inflammatory mediators such as substance P and 
calcitonin gene-related peptide (CGRP) [18] that have 
a relevant effect in vasodilation. The reduction of all 
those mediators can lead to a reduction of local skin 
inflammation and allow erythema to fade out relieving 
at the same time from pain. Reported adverse effect 
to BTX treatment is rare and limited to a mild 
headache. 
In conclusion, the innovative applications for 
BTX use in rosacea and facial flushing treatment, 
even if his complex mechanism is not completely 
understood, suggest that intradermal BTX injections 
are safe and efficacious for reducing erythema and 
flushing in rosacea. Larger, controlled, randomised 
studies are warranted to determine optimal dosing 
and duration of the activity. Moreover, to better 
understand its therapeutic potential in dermatology 
future studies should investigate the link between BTX 
and the cutaneous neuroimmune system and skin-
nervous system interaction. Also, a consensus on the 
dose and regimen would be desirable to standardise 
the treatment. 
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